Michael Traxlmayr
Priv.-Doz. Dipl.-Ing. Dr. Michael Traxlmayr
Institut für Biochemie (DCH/BC)
Standort Gregor-Mendel-Straße 33, 1180 Wien
Email michael.traxlmayr@boku.ac.at
Tel: +43 1 47654-77274
ORCID: 0000-0002-2108-582X
55008094000: AuthorId
Laufbahn
- 2022 Habilitation
- 2017 Senior Scientist (BOKU)
- 2016 - 2017 Postdoc (BOKU)
- 2013 - 2015 Postdoc (Massachusetts Institute of Technology, MIT)
- 2008 - 2012 Dissertation (BOKU)
- 2002 - 2008 Diplomstudium Lebensmittel- und Biotechnologie (BOKU)
Auszeichnungen
- 2020 BOKU invention of the year
- 2013 BOKU Talent Award
- 2013 Schrödinger fellowship for postdoctoral research at MIT
- 2013 ÖGMBT doctoral thesis award (Austrian Association of Molecular Life Sciences and Biotechnology)
Projekte
Es wurden 0 Projekte gefunden.
Publikationen
Wissentransfer in die Gesellschaft
Medienbeiträge
Vorträge
(2024) Engineering of molecular ON- and OFF-switches for controlling CAR T cells
Autoren: Charlotte U. Zajc, Delia Sumesgutner, Julia Mayer, Elise Sylvander, Magdalena Teufl, Manfred Lehner, Michael W. Traxlmayr
EBMT-EHA 6th European CAR T-cell Meeting
(2023) Engineering molecular switches for functional control of CAR T cells with an orally available small molecule drug.
Autoren: Zajc, CU; Dobersberger, M; Schaffner, I; Mlynek, G; Pühringer, D; Salzer, B; Djinović-Carugo, K; Obinger, C; Lehner, M; Traxlmayr, MW
EHA-EBMT 5th European CAR T-cell Meeting
(2023) Novel protein engineering strategies for next-generation CAR T-cells.
Autoren: Traxlmayr, MW
Janssen R&D Symposium on Next-Generation Cell Therapy
(2023) Unraveling the FMC63-CD19 affinity
Autoren: Seigner, J; Zajc, CU; Dötsch, S; Eigner, C; Laurent, E; Busch, DH; Lehner, M; Traxlmayr, MW
Keystone meeting on Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy
(2023) Incorporating drug regulated switch modules to improve the safety of cellular therapies.
Autoren: Traxlmayr, MW
Gamma Delta T Therapies Summit, Boston
(2023) Novel protein engineering concepts to improve the safety and specificity of CAR T cells
Autoren: Traxlmayr, MW
PEGS Boston
(2023) Taking control of CAR T cells- Engineering of molecular ON-switches for cellular therapies
Autoren: Charlotte U. Zajc, Markus Dobersberger, Manfred Lehner and Michael W. Traxlmayr
ÖGMBT Annual Meeting
(2023) Novel Concepts to Regulate CAR T Cell Activity with Small Molecule Drugs in Vivo
Autoren: Traxlmayr, MW
PEGS Europe
(2022) Entwicklung von stabilisierten CD19-Varianten für die Detektion und Affinitätsanalyse von CAR-T Zellen
Autoren: Michael W. Traxlmayr
CAR-T Cell Network Meeting
(2022) PhosphoFlowSeq – a novel high-throughput kinase activity assay for the identification of drug resistance mutations in EGFR
Autoren: Teufl, M; Wagner, A; Gold, L; Lehner, M; Obinger, C; Sykacek, P; Traxlmayr, M
PEGS Europe 2022
(2022) Reversible control of CAR-T therapy to reduce toxicity and improve clinical outcomes
Autoren: Michael W. Traxlmayr
Onco Cell Therapy Summit Europe
(2020) Detailed analysis of lipocalin-based molecular ON-switches in biochemical assays and in CAR T cells
Autoren: Brey, CU; Dobersberger, M; Schaffner, I; Salzer, B; Steinberger, P; De Sousa Linhares, A; Lehner, M; Traxlmayr, MW
Keystone Symposia meeting on Emerging Cellular Therapies: Cancer and Beyond
(2020) A conformation-specific ON-switch for controlling CAR T cells with an orally available drug
Autoren: Brey, C.U.; Dobersberger, M.; Schaffner, I.; Salzer, B.; Obinger, C.; Holter, W.; Traxlmayr, M.W.; Lehner, M.
Keystone-Emerging cellular therapies
(2019) AVIDCARS - A NOVEL PLATFORM FOR INTEGRATION OF MULTIPLE INPUT SIGNALS BY ONE CAR MOLECULE
Autoren: Salzer, B; Brey, CU; Schueller, C; Schoeber, M; Lobner, E; Dushek, O; Holter, W; Traxlmayr, MW; Lehner, M
International Conference on Lymphocyte Engineering (ICLE)
(2019) A LIPOCALIN-BASED ON-SWITCH FOR CONTROLLING CAR T CELLS WITH AN ORALLY AVAILABLE DRUG
Autoren: Brey, C; Dobersberger, M; Schaffner, I; Mlynek, G; P?hringer, D; Salzer, B; Djinovic-Carugo, K; Obinger, C; Holter, W; Traxlmayr, M; Lehner, M
International Conference on Lymphocyte Engineering (ICLE)
(2019) Moderne Krebsforschung – Neue Chancen durch personalisierte Medizin?
Autoren: Heffeter, P; Jäger, U; Traxlmayr, M
Science Talk
(2017) Development of a FACS-based screening for H2O2 producing oxidoreductases using GFP derived sensors
Autoren: Herzog, PL; Brugger, D; Sützl, L; Traxlmayr, M; Obinger, C; Haltrich, D; Peterbauer CK
19th International Symposium on Flavins and Flavoproteins 2017
(2016) Structures and thermodynamics of Fcab-antigen complexes.
Autoren: Lobner, E., Humm, A.-S., Göritzer, K., Mlynek, G., Hasenhindl, C., Traxlmayr, M., Djinoviv-Carugo, K., Obinger, C.
PEGS 2016
(2016) A hyperstable miniprotein as an alternative to antibodies
Autoren: Traxlmayr, MW; Kiefer, JD; Srinivas, RR; Lobner, E; Tisdale, AW; Mehta, NK; Tidor, B; Wittrup KD
8th ÖGMBT Annual Meeting 2016
(2014) A Hyperstable Minimalist Protein for Molecular Recognition
Autoren: Traxlmayr, MW; Srinivas, RR; Lobner, E; Tidor, B; Wittrup, KD
28th Annual Symposium of the Protein-Society 2014
(2014) Construction of pH-sensitive Her2 binding antibody fragment by directed evolution using yeast display
Autoren: Lobner, E., Traxlmayr, M. W., Rueker, F., Obinger, C.
The 16th European Congress on Biotechnology
(2012) Systematic analysis of the C-terminal loops of IgG1-Fc for their usability in Modular Antibody Engineering
Autoren: Hasenhindl, C., Wozniak-Knopp1, G., Traxlmayr, M.W., Hackl, M., Stadlmayr, G., Rüker F. and Obinger C.
9th International Conference on Protein Stability 2012 - From molecular level to market applications
(2012) Measures to Enhance Half-Life and Stability (Preconference Short Course)
Autoren: Rüker, F; Traxlmayr, M;
Protein and Antibody Engineering Summit PEGS Europe 2012
(2012) Stability engineering of human IgG1-Fc to resist boiling
Autoren: Stadlmayr, G., Schaffner, I., Traxlmayr, M., Wozniak-Knopp, G., Hasenhindl, C., Rüker, F. and Obinger, C.
9th International Conference on Protein Stability 2012 - From molecular level to market applications
(2012) Stability engineering of IgG1-Fc and construction of a “protein stability landscape” by high throughput sequencing
Autoren: Traxlmayr, M.W.Faissner, M., Hasenhindl, C., Hackl, M., Stadlmayr, G., Rüker, F. and Obinger, C.
9th International Conference on Protein Stability 2012 - From molecular level to market applications
(2011) Stability engineering of human IgG1-Fc and application in modular antibody engineering
Autoren: Hasenhindl,C., Traxlmayr, M. W., Faissner, M., Stadlmayr, G., Rüker, F., Obinger, C.
3rd PEGS Europe Protein & Antibody Engineering Summit 2011
(2011) Stability-engineering of human IgG1-Fc by using yeast display
Autoren: Traxlmayr, M. W., Faissner, M., Stadlmayr, G., Rüker, F., Obinger, C.
PEGS - Protein and Antibody Engineering Summit 2011
(2009) Engineered human IgG1-Fc binding to integrin
Autoren: Traxlmayr, M., Wozniak-Knopp, G., Rüker, F., Obinger, C.
20th IBC's Annual International Conference on Antibody Engineering 2009
Directed evolution of antibody fragments for improved stability and resistance to aggregation by using yeast surface display
Autoren: Lobner, E., Traxlmayr, M. W., Rüker, F., Obinger, C.
Stability assessment on a library scale – A rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc.
Autoren: Hasenhindl, C., Traxlmayr, M.W., Wozniak-Knopp, G ., Jones, P.C., Stadlmayr, G., Rüker, F., Obinger, C.
Construction of a molecular ON-switch for controlling CAR T cells with an orally available small molecule
Autoren: Brey, CU; Dobersberger, M; Schaffner, I; Mlynek, G; Pühringer, D; Salzer, B; Djinović-Carugo. K; Obinger, C; Holter, W; Lehner, M; Traxlmayr, MW